Overview

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

Status:
Withdrawn
Trial end date:
2021-02-09
Target enrollment:
Participant gender:
Summary
The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Burke Medical Research Institute
Treatments:
Citalopram
Dexetimide
Serotonin
Serotonin Uptake Inhibitors